Inhibition of connective tissue growth factor by small interfering ribonucleic acid prevents increase in extracellular matrix molecules in a rodent model of diabetic retinopathy by Winkler, Jennifer L. et al.
Inhibition of connective tissue growth factor by small interfering
ribonucleic acid prevents increase in extracellular matrix
molecules in a rodent model of diabetic retinopathy
Jennifer L. Winkler, Mamdouh H. Kedees, Yelena Guz, Gladys Teitelman
State University of New York, Downstate Medical Center, Department of Cell Biology, Brooklyn, NY
Purpose: Connective tissue growth factor (CTGF) is a profibrotic factor that induces extracellular matrix (ECM)
production and angiogenesis, two processes involved in diabetic retinopathy (DR). In this study, we examined whether
insulin therapy or a CTGF-specific small interfering RNA (siRNA) administered to diabetic rats decreased the levels of
CTGF and of selected putative downstream genes in the retina.
Methods: Rats with streptozotocin-induced diabetes were used. Animals received either no treatment for 12 weeks or
were administered constant insulin therapy. MRNA and protein levels of CTGF and select ECM genes were determined
using real-time PCR and western blotting of the retina. Localization of CTGF in the retina was visualized using
immunohistochemistry. A group of diabetic rats received intravitreal injection of CTGF siRNA, and the retinas were
examined three days later.
Results: CTGF mRNA and protein significantly increased in the retinas of diabetic rats. Immunohistochemistry indicated
that retinal Müller cells of diabetic rats expressed CTGF. Hyperglycemia upregulated mRNA levels of fibronectin, laminin
β1, collagen IVα3, and vascular endothelial growth factor (VEGF), and this increase was prevented by insulin therapy.
Treatment of diabetic rats with CTGF siRNA decreased laminin β1, collagen IVα3 mRNA, and CTGF mRNA and protein
but did not affect fibronectin or vascular endothelial growth factor mRNA levels.
Conclusions: These results indicate that CTGF and ECM genes can be regulated using insulin. Importantly, these results
also suggest that CTGF regulates changes in ECM molecules in DR.
Diabetic retinopathy (DR) is the leading cause of visual
impairment and blindness among adults of working age in the
United States [1]. DR can be divided into two stages. The first
stage is non-proliferative DR, characterized by retinal edema,
microaneurysms, venous bleeding, and soft exudates. The
second  stage,  proliferative  DR,  is  characterized  by
angiogenesis, retinal detachment, blindness, and an increased
number of blood vessels with altered vascular permeability.
DR occurs because of altered blood flow, pericyte loss, tissue
hypoxia, and basement membrane thickening provoked by
increased production of collagen IV, laminin, and fibronectin
[2-4]. These changes were detected after 12 and 17 weeks
following the appearance of diabetes, respectively [5,6]. In
addition, there is also dysregulation of remodeling proteins
such  as  matrix  metalloproteinease-2,  matrix
metalloproteinease-9  (MMP-9),  plasminogen  activator
inhibitor-1, tissue inhibitor of metalloproteinease-1, and other
proteins [7-9].
Connective tissue growth factor (CTGF) is a profibrotic
factor that induces extracellular matrix (ECM) production and
angiogenesis [10], two processes involved in the development
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of DR. CTGF is one of the six members of the CCN family of
proteins. The CCN acronym is derived from the names of the
first three members of the family of proteins: Cyr61 (cysteine-
rich  protein  61),  CTGF,  and  NOV1  (nephroblastoma
overexpressed  gene-1).  The  CCN  family  of  proteins  is
involved in a wide range of functional pathways such as cell
adhesion,  cell  survival,  angiogenesis,  tumorigenesis,  and
wound  healing  [11].  CTGF  is  upregulated  in  human  and
rodent models of DR [12,13] and is induced by glucose [5,
13] and advanced glycation end-products [5]. In addition,
CTGF is upregulated by vascular endothelial growth factor
(VEGF) [14,15], which is increased in patients with diabetes
and  is  a  critical  regulator  of  vascular  permeability  and
angiogenesis [16].
The exact role of CTGF in the progression of DR has yet
to be determined. Although CTGF knockout is embryonic
lethal [17], CTGF heterozygote mice have a 50% decrease in
CTGF levels in plasma and urine and show decreased retinal
basal lamina thickening in diabetes [6]. In addition, CTGF is
responsible for the development of fibrosis, not angiogenesis,
which results in scarring of the retina and blindness [18].
Studies of the kidney strengthened the possibility that CTGF
mediates the alterations of ECM during hyperglycemia [19].
In this study, we sought to determine the role of CTGF in
non-proliferative DR. First, we tested whether the increase in
CTGF levels with hyperglycemia could be attenuated through
Molecular Vision 2012; 18:874-886 <http://www.molvis.org/molvis/v18/a92>
Received 30 June 2011 | Accepted 4 April 2012 | Published 7 April 2012
© 2012 Molecular Vision
874insulin therapy and whether this treatment affected the level
of expression of key ECM molecules. Since glycemic levels
fluctuate during insulin therapy, we also tested whether a
specific inhibition of CTGF using siRNA affects the levels of
selected ECM molecules that increase in the diabetic retina.
METHODS
Diabetic animal model: Male Sprague Dawley Rats (Charles
River, Troy, NY), weighing approximately 200 g, received a
single (IP) injection of 80 mg/kg streptozotocin (STZ; Sigma,
St. Louis, MO) dissolved in 0.1 M citrate buffer (pH 4.5)
[20]. Control non-diabetic animals were injected with an equal
volume of citrate buffer. Fasting blood glucose (FBG) levels
were measured using a PrecisionXtra blood glucose monitor
(Abbot,  Alameda,  CA).  Animals  with  FBG  greater  than
350 mg/dl were considered diabetic. The first day of recorded
hyperglycemia  was  considered  day  1  of  the  experiment.
Animals were euthanized with Euthasol (120 mg/kg; Vibrac
Corp., Fort Worth, TX) and sacrificed after 8 and 12 weeks of
hyperglycemia. Eyes were enucleated, and the retina dissected
in nuclease free ice-cold PBS (137 mM sodium chloride,
2.7 mM potassium chloride, 8 mM sodium phosphate dibasic,
2 mM potassium phosphate monobasic, pH 7.4). The animal
procedures were in accordance with the institutional Animal
Care and Use Committee and with the standards established
by the New York State Department of Health, the USA Public
Health Service, the USA Department of Agriculture, and the
Association for Assessment and Accreditation of Laboratory
Animal Care.
Cell cultures: Rat-2 fibroblasts (ATCC, Manassas, VA) were
maintained in vitro as previously described [21]. Briefly, cells
were  maintained  in  Dulbeco’s  Modified  Eagle  Medium
(DMEM,  Sigma)  supplemented  with  sodium  bicarbonate
(1.5  g/l;  Invitrogen,  Carlsbad,  CA)  and  10%  fetal  bovine
serum (FBS, Invitrogen). Rat-2 cells were seeded at a density
of 5.8×105 cells in a T-25 tissue culture flask (Falcon; BD, San
Jose, CA) and allowed to adhere overnight. Transfection agent
(siPORT-Amine; Ambion, Austin, TX) was diluted (1:40) in
Opti-MEM (Invitrogen) and incubated at room temperature
for 10 min. Three CTGF siRNAs (Ambion) were individually
tested for their effect on CTGF mRNA and protein. Sequences
for these siRNAs are shown in Table 1. Each siRNA (50 mM),
diluted in 900 µl of Opti-MEM, was added to the transfection
mix  and  incubated  at  room  temperature  for  10  min.  The
siRNA/transfection  agent  complexes  were  added  to
suspended cells (1.8×106), and the mixture was placed in a
T-75  flask  in  medium  containing  10%  FBS.  siRNA
transfected cells were incubated at 37 °C with CO2 for 24 h.
Then the cells were processed and treated with transforming
growth factor (TGF)-β1 (R&D Systems, Minneapolis, MN)
as previously described [21]. In brief, cells were incubated
with 0.5% FBS DMEM medium containing TGF-β1 (0.1 ng/
ml) for 4 or 6 h before harvesting. After TGF-β1 treatment,
cells were trypsinized with 0.25% trypsin-EDTA (Trypsin-
EDTA; Invitrogen) and pelleted by centrifugation at 200 g for
5 min (International Equipment Company, Chattanooga, TN).
Cell pellets were washed in RNase-free ice-cold PBS and
centrifuged at 1,300× g (MTX-150; Tomy Tech, Menlo, CA)
for 10 min at 4 °C and then used for total RNA isolation or
protein extraction.
Insulin therapy: A subset of diabetic animals (FBG≥350 mg/
dl) was implanted with subcutaneous insulin pellets (LinShin
Canada Inc., Toronto, Canada) for 12 weeks, on the first day
of  hyperglycemia  according  to  the  company’s
recommendations. FBG was measured 1 week after insulin
pellet implantation (day 1 of the experiment for the group
treated with insulin), and weekly thereafter. Animals with
poor glycemic control received two additional insulin pellets.
Intravitreal  small  interfering  ribonucleic  acid  injections:
After 12 weeks of hyperglycemia, a subset of rats received a
single  intravitreal  injection  of  siRNA.  Animals  were
anesthetized with vaporized isoflurane. Eyes were visualized
with  a  dissecting  microscope,  and  the  sclera  was  pierced
behind  the  ora  serrata  using  a  borosilicate  glass  capillary
(World Precision Instruments, Sarasota, FL) that was heat
pulled  to  obtain  a  thin  diameter.  siRNAs  (Table  1)  were
modified for in vivo studies by Dharmacon (Lafayette, CO),
using  undisclosed  techniques  due  to  proprietary
considerations.  siRNA  was  diluted  in  sterilized,  RNase/
DNase-free,  physiologic  PBS  for  a  final  concentration  of
2.5 µg/µl. siRNA was injected using a sterilized Nanofill
syringe attached to a 33G beveled needle (World Precision
Instruments) inserted in the opening produced by the capillary
needle. One eye was injected with 3 µl (7.5 µg) of CTGF
siRNA  and  the  contralateral  eye  with  scrambled  siRNA
(7.5 µg). Animals were sacrificed at 3 and 10 days post siRNA
injection.
TABLE 1. SEQUENCES FOR SIRNAS.
Name of siRNA Sense (5′-3′) Antisense (5′-3′)
Scrambled siRNA                                                 Sequence undisclosed by company
CTGF siRNA I * GGAUUACAGUAGCACAUUATT UAAUGUGCUACUGUAAUCCTT
CTGF siRNA II GGGACACGAACUCAUUUAGTT CUAAAUGAGUUCGUGUCCCTT
CTGF siRNA III CGAACUCAUUUAGACUAUATT UAUAGUCUAAAUGAGUUCGTG
Scrambled siRNA* UAAGGCUAUGAAGAGAUACUU PGUAUCUCUUCAUAGCCUUAUU
          *Denotes siRNA used for intravitreal injections.
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875To track and visualize siRNA inside the layers of the
retina, a Label IT siRNA Tracker Kit (Mirus, Madison, WI)
was used to label the scrambled siRNA with Cy3. Briefly,
about  10  mg  of  siRNA  (Silencer®  Negative  Control  #2
siRNA; Ambion) was incubated with 5 μl labeling buffer A
(Mirus) and 10 μl labeling reagent (Mirus) at 37 °C for 1 h,
unreacted Label IT siRNA Tracker Reagent was removed
from  the  labeled  siRNA  with  ethanol  precipitation,  and
labeled  siRNA  was  spun,  washed  with  ethanol  70%,  and
resuspended in PBS. Purified, labeled siRNA was quantified
with spectrophotometry. Five μg (in 2 μl PBS) of labeled
siRNA was injected in one eye. The contralateral eye was
injected with the same volume of unlabeled siRNA. Eyes were
enucleated 3 days later, placed in mounting medium, snap
frozen in liquid nitrogen, and cryosectioned, and cells were
visualized  by  staining  the  nuclei  with  To-Pro  Blue
(Invitrogen).
Immunohistochemistry:  Animals  were  euthanized,  and  the
eyes were immersed in embedding matrix (ThermoFisher,
Waltham, MA) and snap frozen in liquid nitrogen. Then 20 µm
sections were obtained. The plane of section was parallel to
the optic nerve. Cryosections were fixed in ice-cold acetone
(10 min), and post-fixed in Zamboni’s fixative for 2 min.
Slides were washed in 0.1 M PBS, and sequentially incubated
in PBS containing 0.3% hydrogen peroxide for 20 min, in
blocking buffer (PBS containing 3% horse serum and 0.01%
saponin) for 30 min, and incubated with goat anti-human
CTGF antibody (diluted 1:100 in 0.01 M PBS; R&D) at 4 °C
overnight. The specificity of this antibody has been previously
described [22-26]. The next day, slides were incubated for 1
h  with  Alexa  Fluor  488  conjugated  with  antigoat
immunoglobulin G (diluted 1:200 in 0.01 M PBS; Invitrogen),
washed in PBS, fixed in 4% paraformaldehyde for 5 min, and
incubated  overnight  with  mouse  anti-vimentin  antibody
(1:500  in  0.01  M  PBS).  The  following  day,  slides  were
incubated for 1 h with Alexa-Fluor 594 (1:200 in 0.01 M PBS;
Invitrogen)  and  coverslipped  using  Vectashield  mounting
medium (Vector, Burlingame, CA).
Confocal microscopy: Confocal images were obtained using
a Radiance 2000 confocal microscope (Bio-Rad, Hercules,
CA) connected to a Zeiss Axioskop microscope (Carl Zeiss,
Thornwood,  NY).  Images  of  1240×1240  pixels  were
processed  using  Photoshop  (Adobe,  San  Jose,  CA).  All
images were captured using similar settings on the confocal
microscope.
Quantitative real-time polymerase chain reaction: Total RNA
was extracted using the RNAeasy Kit (Qiagen, Germantown,
MD) as described in Winkler et al. [21]. Briefly, concentration
and purity of RNA were determined by spectrophotometry.
RNA  integrity  was  verified  by  electrophoresis  in  1.2%
denaturing formaldehyde gel (1.2 g agarose, 10 ml 10× FA
gel buffer [200 mM 3-[N-morpholino] propanesulfonic acid;
MOPS], 50 mM sodium acetate, 10 mM EDTA, pH 7.0) in
100 ml RNase-free water). RNA preparations were treated
with  recombinant  DNase-1  (DNA-free  kit;  Ambion).  One
microgram of total RNA was transcribed using SuperScript
III reverse transcriptase and oligo(dT)18 primer (Invitrogen).
Real-time PCR was performed using RT2 SYBR Green Mix
(SA  Biosciences,  Frederick,  MD)  and  performed  on  a
StepOnePlus cycler (Applied Biosystems, Carlsbad, CA). The
cycling conditions were 95 °C for 10 min, 40 cycles at 95 °C
for 15 s, and 60 °C for 1 min. mRNA levels were normalized
to an appropriate housekeeping gene, TATA-binding protein
(TBP)  [27]  or  acidic  ribosomal  protein  P0  (ARPP0)  [28].
Primer sequences for laminin β1, fibronectin 1, and collagen
IVα3 were taken from a previous publication [5]. Details of
the primers are shown in Table 2. Data was analyzed using
the 2-∆∆C(T) method [29]. Each sample was run in triplicate, and
each real-time PCR was repeated three times.
Western blot analysis: Retinas were homogenized for 5 min
in ice-cold lysis buffer (50 mM Tris HCl, pH 7.4, 5 mM
EDTA, and 0.02% sodium azide) containing a cocktail of
protease inhibitors (Sigma). After homogenization, samples
were centrifuged at 28,000× g for 10 min at 4 °C. Protein
concentration  in  cleared  lysates  was  measured  using
bicinchoninic  acid  colorimetric  assay  (BCA  kit;  Pierce,
Rockford, IL). Samples were fractionated on a 15% Tris-HCl
sodium  dodecyl  sulfate–PAGE  (SDS–PAGE)  Ready  Gel
(Bio-Rad) for CTGF and VEGF and a 5% Tris-HCl SDS–
PAGE Ready Gel (Bio-Rad) for laminin; 30 µg of total protein
was  loaded  into  each  lane.  After  electrophoresis,  protein
samples were electroblotted onto nitrocellulose membrane
(Amersham, Pittsburgh, PA), washed in Tris-buffered saline,
and incubated overnight at 4 °C with goat anti-CTGF antibody
(1:1,000;  Santa  Cruz,  Santa  Cruz,  CA).  Membranes  were
incubated with horseradish peroxidase–conjugated Donkey
anti-goat  secondary  antibody  (1:10,000;  Santa  Cruz),  and
bands  were  visualized  using  SuperSignal  West  Pico
chemiluminescent detection reagents (Thermo Scientific) and
Hyblot-CL Autoradiography Film (Denville, Metuchen, NJ).
Membranes were subsequently stripped with Restore Western
Blot Stripping (Thermo Scientific), incubated with antibodies
to  VEGF  (1:1,000;  Santa  Cruz)  and  to  glyceraldehyde  3-
phosphate dehydrogenase (GAPDH; 1:1,000; Santa Cruz) for
loading  control,  and  processed  for  immunodetection  as
described as above. GAPDH was chosen because changes in
protein levels have been reported in vivo only after 12 months
of hyperglycemia [30]. Different membranes were incubated
with anti-laminin sera, a pan-specific antibody that recognizes
multiple laminin isoforms (1:1,000; Novus, Littleton, CO).
For loading controls, membranes were stained with Ponceau
S.  Densitometric  analysis  of  the  luminescent  signal  was
performed at non-saturating exposures. Bands were scanned
with  Epson  Perfection  2400  and  analyzed  using  Image  J
software (NIH, Bethesda, MD). Densitometry was performed
using proteins that were run on the same gel.
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877Statistical analysis: All values are shown as mean±SD. For
comparison between two groups, the unpaired Student t test
(two tail) was used. p≤0.05 was considered significant.
RESULTS
Connective tissue growth factor messenger ribonucleic acid
and protein increased because of hyperglycemia: To ascertain
whether  CTGF  gene  expression  increased  during
hyperglycemia, the level of CTGF mRNA and protein in the
retina of diabetic and non-diabetic control rats was compared.
At 8 and 12 weeks of hyperglycemia, CTGF mRNA was
sixfold  (p<0.05)  and  sevenfold  (p<0.001)  higher  than  in
controls, respectively (Figure 1A and Figure 2A). Similarly,
CTGF protein increased 2.5 fold (p<0.05) at 8 weeks and 5.7
fold (p<0.05) at 12 weeks of hyperglycemia (Figure 1B,C and
Figure 2B,C). These findings are in agreement with previous
reports by others [5,12,13]. To ascertain the identity of the
cells expressing CTGF, sections of retina were processed for
simultaneous visualization of CTGF and vimentin, a marker
of Müller cells [31]. This analysis indicated that in the retina
of  diabetic  rats,  CTGF  is  expressed  by  vimentin-positive
Müller cells (Figure 3).
In  addition  to  an  increase  in  CTGF,  hyperglycemia
affected the level of expression of VEGF and of possible
downstream ECM genes in the retina. Comparison of the
retina of 12-week diabetic and normoglycemic rats revealed
a  significant  increase  in  fibronectin  (threefold,  p<0.001),
laminin  β1  (2.5  fold,  p<0.05),  collagen  IVα3  (2.3  fold,
p<0.05), and VEGF (twofold, p<0.001) mRNAs (Figure 2A).
Figure  1.  Connective  tissue  growth
factor (CTGF) expression increased in
retina of 8 and 12 week diabetic rats.
CTGF mRNA expression in the retinas
of non-diabetic and diabetic rats after 8
and 12 weeks of hyperglycemia were
analyzed  using  real-time  PCR  and
normalized  to  the  housekeeping  gene
acidic  ribosomal  phosphoprotein  P0
(ARPP0).  A:  CTGF  mRNA  levels
increased six- and sevenfold at both time
points. B: A representative western blot
illustrating  CTGF  and  glyceraldehyde
3-phosphate dehydrogenase (GAPDH)
protein  expression  in  the  retinas  of
diabetic rats after 8 and 12 weeks of
hyperglycemia.  Note  the  increased
CTGF protein levels compared to the
non-diabetic controls. C: Densitometric
analysis of three separate immunoblots
indicates a 2.5 and 5.7 fold increase in
the CTGF protein after 8 and 12 weeks
of  hyperglycemia,  respectively.
(*p<0.05,  **p<0.001  diabetic  versus
non-diabetic)  n=non-diabetic;
D=diabetic. Proteins ran on a 4%–15%
gradient gel. n=3/age.
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878Protein  levels  of  VEGF  and  laminin  also  increased
significantly (2.1 fold and 5.2 fold, respectively [p<0.05]) in
the retina after 12 weeks of hyperglycemia (Figure 2D,E).
These results confirm previous observations obtained using a
similar model [4,32].
Insulin  therapy  regulates  the  levels  of  connective  tissue
growth  factor,  vascular  endothelial  growth  factor,  and
extracellular matrix molecules: To ascertain whether insulin
therapy affects the level of expression of CTGF, VEGF, and
possible downstream ECM molecules in the retina, a subset
of rats with STZ-induced diabetes received insulin therapy at
Figure 2. Insulin therapy in diabetic rats
abolished  hyperglycemia-induced
increases in levels of selected genes and
proteins.  mRNA  expression  in  the
retinas  of  non-diabetic,  diabetic,  and
diabetic rats treated with insulin were
analyzed  using  real-time  PCR  and
normalized  to  the  housekeeping  gene
acidic  ribosomal  phosphoprotein  P0
(ARPP0). A: Real-time PCR analysis of
mRNA extracted from the retina. Note
the increase in the levels of connective
tissue growth factor (CTGF; sevenfold),
fibronectin (threefold), laminin β1 (2.5-
fold),  collagen  IVα3  (2.3  fold),  and
vascular  endothelial  growth  factor
(VEGF;  twofold)  mRNAs  in  the  rat
retinas after 12 weeks of hyperglycemia
and  that  this  increase  was  prevented
with insulin therapy. B: A representative
immunoblot showing CTGF expression
in the retinas of normoglycemic control,
diabetic,  and  insulin-treated  rats.
Proteins were ran on a 15% SDS–PAGE
gel,  allowing  for  better  protein
separation, hence the double band for
CTGF.  C:  Densitometric  analysis  of
three different western blots indicated
that  the  level  of  CTGF  increased
following 12 weeks of hyperglycemia,
when  compared  to  the  non-diabetic
controls. In contrast, CTGF expression
in the retinas of diabetic rats treated with
insulin for 12 weeks remained near the
control  levels.  D:  A  representative
western blot for VEGF and laminin in
retinal  extracts  shows  an  increase  in
retinal  VEGF  and  laminin  in  the
hyperglycemic state, and this increase
was  inhibited  in  the  insulin-treated
hyperglycemic  rats.  E:  Densitometric
analysis of three different western blots
revealed a 2.1-fold increase in VEGF
and a 5.2-fold increase laminin. VEGF
and laminin levels were similar in the
control  and  insulin-treated  diabetic
animals.  GAPDH  and  Ponceau  S
staining were used as a loading control.
n=non-diabetic;  D=diabetic;  D
+IN=insulin treated diabetic (*p<0.05,
**p<0.001). n=3/group.
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8797 days post-STZ for 12 weeks. Insulin therapy normalized
blood glucose levels and reduced weight loss in diabetic rats
(Table  3).  The  levels  of  CTGF,  fibronectin,  laminin  β1,
collagen IVα3, and VEGF mRNAs in the retinas of diabetic
rats receiving insulin therapy were similar to that of controls
(Figure 2A). Similarly, CTGF, VEGF, and laminin proteins
were similar in insulin-treated STZ and non-diabetic control
(Figure 2B-E). To confirm the effect of insulin on CTGF, the
levels of CTGF in the retinas of the control, diabetic, and
insulin-treated  diabetic  rats  were  compared  with
immunohistochemistry. The level of CTGF immunostaining
was undetectable in control retinas (Figure 4A), increased in
diabetic retinas (Figure 4B), and significantly reduced in the
retinas of diabetic rats treated with insulin (Figure 4C). In
addition, we confirmed previous reports indicating that insulin
treatment  normalized  fibronectin  levels  in  the  retinas  of
diabetic rats (Figure 2A) [33]. These findings indicate that
insulin  prevented  the  glucose-dependent  increase  in  the
expression of these selected cytokines and ECM genes.
Effect of connective tissue growth factor small interfering
ribonucleic acid on the expression of connective tissue growth
factor and possible downstream targets: To further analyze
the contribution of CTGF in regulating ECM molecules, we
developed a siRNA-approach to inhibit CTGF. We tested if
inhibition  of  CTGF  by  siRNA  affected  the  expression  of
laminin  β1,  fibronectin  1,  collagen  IVα3,  and  VEGF.  In
addition, we also tested the effect of the treatment on glial
fibrillary  acidic  protein  (GFAP),  an  intermediate  filament
protein that increases in the retina during DR [34,35],
We  first  used  an  in  vitro  system  to  determine  the
specificity of three siRNAs in downregulating CTGF levels
in a rat cell line. Since we previously showed that TGF-β
induces a twofold increase in CTGF mRNA and a significant
increase in the CTGF protein in Rat-2 fibroblasts [21], we
tested whether the induction of CTGF was inhibited by any of
Figure 3. Connective tissue growth factor (CTGF) was detected in vimentin-positive Müller cells in the retina of diabetic rats. A: Müller cells
labeled with filament protein vimentin throughout the diabetic retina. B: CTGF staining in the 12-week diabetic retina is also seen throughout
the retina. C: Merge photomicrograph for vimentin and CTGF shows that CTGF colocalizes with vimentin in the diabetic retina. Bar=60 um.
D: High magnification of the area indicated with a dotted rectangle in C. Bar=5 um. V=Vitreous, ONL=Outer Nuclear Layer, S=Sclera.
TABLE 3. AVERAGE BLOOD GLUCOSE AND WEIGHT OF CONTROL, DIABETIC AND INSULIN TREATED ANIMALS.
Parameter Control (non-diabetic) n=6 Diabetic (untreated) n=12 Insulin treated diabetic n=8
Blood glucose (mg/dl) 117±13.8 405±68 135±89
Weight (g) 729±52 335±71 524±60
Figure 4. Hyperglycemia induces connective tissue growth factor (CTGF) expression in Müller cells. A representative photomicrograph
illustrates retinas processed for visualization of CTGF. The CTGF level is low in the retinas of the control rats (A) and increased in the retinas
of the diabetic rats after 12 weeks of hyperglycemia (B). Insulin therapy for 12 weeks decreased the staining intensity of CTGF (C). All images
were captured at the same magnification. V=vitreous side of the retina. Bar=30 um. n=3/group.
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880the  three  CTGF  siRNAs  (siRNA  I–III)  alone  or  in
combination.  Previous  studies  showed  that  CTGF  protein
levels in Rat-2 cells were undetectable in the absence of TGF-
β [21]. Real-time PCR showed that siRNA I and siRNA III
decreased TGF-β induced CTGF mRNA by 75% and 86%
(p<0.05), respectively (Figure 5A). In contrast, siRNA II had
no  effect  on  reducing  CTGF  mRNA  (data  not  shown).
Western blot analysis using siRNA I and siRNA III revealed
that CTGF protein decreased by 49% and 46%, respectively
(Figure 5B,C). The combination of siRNA I and III did not
result in further inhibition of CTGF (data not shown). siRNA
I was chosen for the in vivo experiments because it gave the
greatest decrease in CTGF protein.
Then we sought to determine whether the siRNA reached
all layers of the retina. Animals were given a single intravitreal
injection of Cy3-labeled scrambled siRNA, and the eyes were
harvested 3 days after the injection, sectioned, and viewed
using confocal microscopy. Labeled siRNA was distributed
throughout  the  retina  from  the  ganglion  cell  to  the
photoreceptor layers (Figure 6A,B,D). The contralateral eyes
were injected with unlabeled siRNA to test whether the light
emissions observed in the eyes injected with labeled siRNA
was due to autofluorescence produced by the siRNA. Retinas
of  rats  that  received  unlabeled  siRNA  did  not  show  any
detectable  fluorescence  (Figure  6C).  The  distribution  of
labeled  siRNA  throughout  the  retina  confirms  previous
reports by Shen et al. [36].
To  determine  whether  the  siRNA  treatment  had  a
beneficial  effect  on  the  retinas  of  diabetic  rats,  12-week
hyperglycemic rats were given a single intravitreal injection
Figure  5.  siRNA  decreased
transforming  growth  factor-β1  (TGF-
β)-induced  connective  tissue  growth
factor  (CTGF)  in  Rat-2  fibroblasts.
CTGF mRNA expression in Rat-2 cells
treated  with  TGF-β  and  siRNA  were
analyzed  using  real-time  PCR  and
normalized  to  the  housekeeping  gene
acidic  ribosomal  phosphoprotein  P0
(ARPP0). A: The effect of two separate
CTGF siRNAs (I and III) and a control
scrambled  siRNA  on  TGF  β-induced
CTGF expression in Rat-2 fibroblasts
was tested. Real-time PCR showed that
siRNA  I  and  siRNA  III  decreased
CTGF  mRNA  by  75%  and  86%,
respectively.  B:  Arepresentative
western blot documenting that TGF-β
induced  CTGF  protein  decreased  by
siRNA I and III. Proteins were run on
the same gel, but not in adjacent lanes.
C: Densitometric analysis summarizing
the  results  of  three  separate  western
blots shows that siRNA I and siRNA III
decreased CTGF protein by 49% and
46%,  respectively.  (*p<0.05).  n=3/
group.
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881of CTGF siRNA in one eye (the experimental retina), while
the contralateral eye was injected with scrambled siRNA (the
control retina). Three days later, the retinas were dissected and
processed  for  mRNA  and  protein  analysis.  Administering
CTGF siRNA induced a decrease in CTGF (33%, p<0.05),
collagen IVα3 (71%, p<0.05), and laminin β1 (63%, p<0.05)
mRNA levels (Figure 7A). Levels of GFAP mRNA decreased
by 44% (p<0.05) in the CTGF siRNA–treated retina (Figure
7A). Importantly, the level of CTGF protein was 54% lower
(p<0.05) in the experimental retinas compared to the control
retinas  (Figure  7B-C).  In  contrast,  administering  CTGF
siRNA  did  not  affect  VEGF  or  fibronectin  levels,  which
remained  similar  in  the  experimental  and  control  retinas
(Figure 7A). The effect of the siRNA treatment decreased with
time  since  the  CTGF  mRNA  levels  were  similar  in  the
experimental and control retinas 10 days after CTGF siRNA
was injected (Figure 7D).
DISCUSSION
Although insulin therapy aids in preventing DR, since insulin
stabilizes  endothelial  barrier  function  [37]  and  decreases
microvascular leakage [38], the role of insulin in regulating
ECM molecules is not well defined. In this study, our first goal
was  to  determine  whether  CTGF,  a  profibrotic  molecule
induced  by  high  glucose  [5,13],  was  downregulated  with
insulin  therapy  and  whether  this  decrease  also  affected
extracellular matrix components proposed to be controlled by
CTGF  [19].  We  found  that  the  elevated  levels  of  CTGF
mRNA and protein induced by hyperglycemia were prevented
by exogenous insulin treatment. Moreover, insulin therapy
also inhibited the upregulation of several components of the
extracellular matrix such as laminin β1, collagen IVα3, and
fibronectin, and of GFAP and VEGF.
Importantly,  we  determined  that  Müller  cells  in  the
diabetic retina immunostained with a specific antibody to
CTGF.  Although  CTGF  is  a  secreted  protein,  it  is  not
surprising that it is localized within the cytoplasm of Müller
Figure 6. Intravitreal injection of labeled siRNA penetrates the retina. A: Confocal microscopy revealed that the scrambled siRNA covalently
bound to Cy3 (Red) was distributed throughout the layers of the retina when injected into the eyes of control rats. The label was distributed
throughout the retina from the ganglion cell layer (GCL) to the photoreceptor layer (PRL). Nuclei were stained with To-Pro Blue. B: A
photomicrograph illustrates panel A with To-Pro Blue removed. Note the distribution of Cy3 labeled siRNA throughout the layers of the
retina. C: In contrast, the retinas of rats injected with unlabeled scrambled siRNA did not contain labeled particles, indicating that the label
was not due to autofluorescence or artifacts from the injection. Bar=30 um. D: Illustrates higher magnification of inset depicted with dotted
rectangle in A. Bar=15 um. IPL=inner plexiform layer, INL=inner nuclear layer. n=3/group.
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882cells. Other secreted proteins, such as hormones, are also
localized to the cytoplasm of the cells that synthesize them.
In contrast to our findings, previous immunohistochemical
studies  reported  the  expression  of  CTGF  by  cells  of  the
ganglion cell and inner plexiform layers in rodents [5,15] and
in  microglial  cells  and  pericytes  in  humans  [12].  The
discrepancy between our results and that of others could be
due to the different histological techniques employed in the
analysis and/or to the specificity of the antibodies used. In situ
hybridization studies reported the expression of CTGF mRNA
by  structures  located  in  the  ganglion  cell  layer  [13]  and
proposed that it was expressed by the end feet of Müller cells
[13].  Although  in  situ  hybridization  identifies  the  site  of
mRNA expression, identifying the cell type that is labeled is
often  difficult.  For  that  reason,  we  used
immunohistochemistry to visualize CTGF. Our results are in
agreement  with  the  cell  type  proposed  by  that  group  to
synthesize CTGF. The antibody did not stain CTGF bound to
the cell membrane of cells that respond to the action of this
cytokine. Although a specific CTGF receptor has not yet been
identified, CTGF appears to perform many of its functions
through integrins, heparin sulfate–containing proteoglycans,
and the low-density lipoprotein receptor–related protein [39].
Although  CTGF  probably  binds  to  any  or  all  of  these
receptors, its levels at the cell membrane are probably below
the sensitivity of the techniques used.
Müller cells become activated by high glucose levels and
upregulate the expression of GFAP, and of VEGF and other
Figure 7. siRNA treatment significantly
decreased  hyperglycemia-induced
increase  in  connective  tissue  growth
factor (CTGF) mRNA and protein, glial
fibrillary  acidic  protein  (GFAP),
collagen  IVα3  and  laminin-β1  gene
expression.  mRNA  expression  for
CTGF and selected genes in the retinas
of the diabetic rats after 12 weeks of
hyperglycemia  were  analyzed  using
real-time  PCR  and  normalized  to  the
TATA-binding protein (TBP). A: Real-
time  PCR  revealed  that  3  days  post
intravitreal  injection,  CTGF  siRNA
induced  a  decrease  in  CTGF  (33%),
GFAP (44%), collagen IVα3 (71%), and
laminin β1 (63%) mRNAs. In contrast,
CTGF siRNA did not affect the level of
fibronectin  or  vascular  endothelial
growth factor (VEGF). B: Immunoblot
analysis of CTGF levels in the retinas
following a single intravitreal injection
of CTGF siRNA or scrambled siRNA
into left and right eye, respectively. The
concentration of the CTGF protein is
lower  in  eyes  injected  with  CTGF
siRNA.  C:  Densitometric  analysis  of
three independent experiments revealed
a  54%  decrease  in  CTGF  protein  in
retinas  injected  with  CTGF  siRNA
compared  to  retinas  injected  with  a
scrambled  (non-specific)  siRNA.
Glyceraldehyde  3-phosphate
dehydrogenase (GAPDH) was used as
loading  control.  D:  Real-time  PCR
showed that CTGF siRNA had no effect
on  CTGF  expression  10  days  after
injection. (*p<0.05). n=5/group.
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883angiogenic cytokines [35,40]. The localization of CTGF to
Müller cells has important clinical applications since these
cells participate in maintaining the homeostasis of the retinal
extracellular  milieu  and  protect  neurons  via  a  release  of
neurotrophic factors; disturbance of these cells could lead to
retinal dysfunction [40].
Although  insulin  therapy  downregulated  the  level  of
expression  of  CTGF  and  ECM  molecules,  oscillations  in
blood glucose occur even in the presence of tight glycemic
control [41], and these changes could affect retinal function
even in well controlled patients [42]. To circumvent possible
harmful effects of blood glucose oscillations, we sought to
develop  a  siRNA  approach  for  short-term  inhibition  of
CTGF. Our goal was to determine whether a reduction in
CTGF expression in diabetic rats affected the activity of genes
regulating  the  synthesis  of  selected  ECM  molecules.  We
found  that  the  siRNA  treatment  specifically  decreased
CTGF  expression  in  vitro  and  in  vivo.  In  vivo,  siRNA
molecules labeled with Cy3 were found in all layers of the
retina. This observation suggests that the injected molecule
reaches all retinal cells but affects only the level of CTGF
expression by Müller cells. Since other retinal cell types do
not express CTGF, their gene expression is not likely to be
affected  due  to  the  exquisite  specificity  of  the  siRNA
approach.
We  demonstrated  that  siRNA  treatment  decreased
CTGF mRNA and protein. This effect is specific, because the
treatment downregulated the 36–38 kDa form of CTGF, the
primary form of the cytokine [43]. In contrast to our finding,
a recent study using a similar approach reported a decrease in
a 55 kDa protein probed with a CTGF antibody and no change
in the 36–38 kDa forms [44]. The identity of the 55 kDa
protein is unknown. Moreover, the specificity of the siRNA
treatment in Yang et al.’s report is unclear since the synthetic
oligonucleotides used in that report also decreased VEGF
[44]. In contrast, in our study the CTGF siRNA did not affect
VEGF mRNA levels, supporting multiple reports indicating
that VEGF is upstream of CTGF [14,15,45].
Our results reveal that the CTGF-specific siRNA resulted
in a decrease in laminin β1 and collagen IVα3 mRNA levels,
indicating that these two genes are CTGF targets. In contrast,
inhibition of CTGF did not change fibronectin mRNA levels.
This result was unexpected because studies in other tissues
reported that CTGF regulates fibronectin expression [19,46].
This discrepancy could be due to differences in the half-life
of fibronectin mRNA in different cell types. We also found
that CTGF siRNA reduced GFAP expression, indicating that
CTGF  regulates  the  level  of  expression  not  only  of
extracellular molecules but also genes coding for intracellular
proteins.  We  did  not  examine  the  protein  levels  of  ECM
molecules following the siRNA treatment. The short duration
of action of the siRNA and the relatively long half-life of
extracellular matrix proteins [47] suggest that, in our studies,
the siRNA treatment did not affect protein levels.
Although  the  siRNA  experiments  support  a  role  for
CTGF in regulating ECM molecules, the effect of the injected
siRNA  in  diabetic  rats  lasted  for  only  3  days  since  the
experimental  and  contralateral  control  retinas  expressed
similar levels of CTGF mRNA 10 days after the injection.
Other  studies  also  reported  a  short  duration  of  siRNA
treatments [36,48]. Therefore, although our findings support
the use of an siRNA approach to complement insulin therapy,
future studies should seek to circumvent its limitations. One
limitation  of  siRNA  treatment  is  the  ability  of  siRNA  to
nonspecifically bind to toll-like receptor 3, resulting in an off-
target antiangiogenic response [49]. In addition, the approach
requires  the  development  of  chemically  modified  siRNA
molecules that will stabilize and extend the duration of the
treatment  when  combined  with  appropriate  transfection
reagents. In conclusion, our results clearly demonstrate that
CTGF regulates the level of expression of ECM molecules as
well as GFAP, a specific glial cell filament.
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